- Home
- MAC vs RNA Comparison
MAC vs RNA Comparison
Compare MAC & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAC
- RNA
- Stock Information
- Founded
- MAC 1964
- RNA 2012
- Country
- MAC United States
- RNA United States
- Employees
- MAC N/A
- RNA N/A
- Industry
- MAC Real Estate Investment Trusts
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- MAC Real Estate
- RNA Health Care
- Exchange
- MAC Nasdaq
- RNA Nasdaq
- Market Cap
- MAC 4.6B
- RNA 4.4B
- IPO Year
- MAC 1994
- RNA 2020
- Fundamental
- Price
- MAC $20.27
- RNA $31.82
- Analyst Decision
- MAC Hold
- RNA Strong Buy
- Analyst Count
- MAC 11
- RNA 11
- Target Price
- MAC $18.42
- RNA $64.36
- AVG Volume (30 Days)
- MAC 3.5M
- RNA 1.4M
- Earning Date
- MAC 02-05-2025
- RNA 11-07-2024
- Dividend Yield
- MAC 3.36%
- RNA N/A
- EPS Growth
- MAC N/A
- RNA N/A
- EPS
- MAC 0.36
- RNA N/A
- Revenue
- MAC $788,288,000.00
- RNA $10,117,000.00
- Revenue This Year
- MAC N/A
- RNA N/A
- Revenue Next Year
- MAC $2.92
- RNA N/A
- P/E Ratio
- MAC $56.58
- RNA N/A
- Revenue Growth
- MAC N/A
- RNA N/A
- 52 Week Low
- MAC $12.99
- RNA $8.86
- 52 Week High
- MAC $22.27
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- MAC 47.15
- RNA 31.67
- Support Level
- MAC $19.67
- RNA $30.07
- Resistance Level
- MAC $21.80
- RNA $34.35
- Average True Range (ATR)
- MAC 0.64
- RNA 2.21
- MACD
- MAC -0.25
- RNA -0.47
- Stochastic Oscillator
- MAC 23.08
- RNA 15.36
About MAC Macerich Company (The)
The Macerich Company invests in premium mall assets. The company owns 28 regional malls in its consolidated portfolio and 14 regional malls in its unconsolidated portfolio along with three power centers and seven other real estate assets. The company's total portfolio has 45.5 million square feet of gross leasable area and averaged $836 sales per square foot over the 12 months ended in December 2023.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.